AriBio Reports Mixed Phase 3 Results for Oral AR1001 in Early Alzheimer’s Disease

18 November 2026 | Wednesday | News

The Phase 3 POLARIS-AD trial showed a statistically significant 31% slowing of clinical decline at 52 weeks in patients receiving AR1001 as monotherapy, but failed to meet statistical significance in the overall study population of 1,535 participants. AriBio plans to review the findings with the US FDA to determine the next steps for its once-daily oral treatment
Image Source: Public Domain

Image Source: Public Domain

AR1001 met the primary endpoint in the prespecified Monotherapy population, with a CDR-SB treatment difference of -0.44 points versus placebo at Week 52 (p=0.0266), representing 31% slowing of clinical decline.

The difference between treatment and placebo in the Overall population numerically favored AR1001 but did not reach statistical significance.

Cognitive and functional secondary measures trended in favor of AR1001 across both populations, with a nominally significant MMSE finding in the Monotherapy population.

CSF biomarker findings support AR1001 target engagement in the central nervous system.

Topline results presented at CTAD 2026. AriBio plans to discuss the results with the FDA.

AriBio Co., Ltd., a biotechnology company developing therapies for neurodegenerative diseases, announced topline results from POLARIS-AD, its global Phase 3 trial of once-daily oral AR1001 in early Alzheimer’s disease (AD).

The primary endpoint was evaluated in two prespecified primary populations, Overall and Monotherapy. The Monotherapy population was comprised of participants not receiving an acetylcholinesterase inhibitor or memantine at baseline. The study met its primary efficacy objective in the prespecified Monotherapy population (n=604), with AR1001 demonstrating a statistically significant treatment difference of −0.44 points versus placebo on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at Week 52 (p=0.0266), representing 31% slowing of clinical decline. In the Overall population (n=1,535), the treatment difference was −0.11 points versus placebo (p=0.4015), numerically favoring AR1001 but not reaching statistical significance.

“We started developing AR1001 with the goal of creating an oral treatment that could slow Alzheimer’s progression and be practical for patients and care partners to use over the long term,” said Jai-Jun Choung, Ph.D., Chairman and Chief Executive Officer of AriBio. “The 31% slowing of clinical decline at one year in the Monotherapy population supports our hypothesis. Our vision is to broaden the treatment options available to patients and families with a once-daily oral medicine. We are deeply grateful to the participants, care partners, investigators and clinical teams who made this global study possible.”

Secondary cognitive and functional measures numerically favored AR1001 in both populations, with larger effects in the Monotherapy population. In the Monotherapy population, AR1001 showed a treatment difference of -1.16 points versus placebo on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog 13; p=0.0798). AR1001 also showed a 0.7-point treatment difference versus placebo on the Mini-Mental State Examination (MMSE; p=0.0232).

In prespecified CSF biomarker analyses, AR1001 increased cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) levels versus placebo at Week 52 in both the Overall and Monotherapy populations (p<0.0001 and p=0.0058, respectively). These findings are consistent with its mechanism of action and support target engagement within the central nervous system. CSF p-tau217 results numerically favored AR1001 in both populations, with treatment differences versus placebo of -3.52 pg/mL in the Overall population (p= 0.1784) and -5.34 pg/mL in the Monotherapy (p=0.0402). No difference in the CSF Aβ42/40 ratio was observed at 52 weeks. Additional biomarker analyses are ongoing to further characterize AR1001’s biological effects.

AR1001 was generally well tolerated over the 52-week treatment phase. Treatment-emergent adverse events occurred in 69.0% of participants receiving AR1001 and 66.4% of those receiving placebo, and serious adverse events were similarly balanced (10.0% vs. 9.8%). Most adverse events were mild to moderate in severity. Fatal adverse events were reported in four participants (0.5%) receiving AR1001 and two (0.3%) receiving placebo. The most common non-serious adverse events with AR1001 were diarrhea (7.7% vs. 4.4% with placebo), falls (7.3% vs. 5.9%) and dizziness (6.1% vs. 3.1%). Adverse events led to discontinuation of study drug in 5.2% of AR1001-treated participants and 1.7% of placebo-treated participants. The most common adverse events that led to study drug discontinuation were diarrhea (0.7% vs 0% with placebo) and vomiting (0.4% vs 0%).

“The CDR-SB finding in the prespecified Monotherapy population and the safety profile are encouraging. The secondary endpoints and biomarker findings warrant further evaluation alongside the Overall population outcome to understand AR1001’s therapeutic effects in early Alzheimer’s disease,” said Sharon J. Sha, M.D., M.S., Chief of the Memory Disorders Division at Stanford University and Global Principal Investigator of POLARIS-AD. “The work of POLARIS-AD is another step towards filling an unmet need in early Alzheimer’s disease in which patients need more options for treatment."

“Participating in the 52-week treatment phase and the ongoing extension takes a sustained commitment from each participant and care partner,” said James Rock, Chief Clinical Officer of AriBio. “We are immensely thankful to our clinical trial sites, participants and caregiver for their unwavering support and dedication to this trial. The ongoing extension phase of the trial will provide important data for understanding disease progress in the context of AR1001 treatment and inform us on the next stage of development for AR1001. We will continue our review of the data and discuss the complete findings with the FDA to inform next steps.”

Dr. Sharon J. Sha presented the POLARIS-AD topline results at CTAD 2026 on Monday, November 16 in Boston. The presentation addressed efficacy and safety outcomes in the Overall and Monotherapy populations.

AriBio plans to present additional analyses at future scientific conferences and discuss the complete findings with the U.S. Food and Drug Administration to inform next steps for AR1001

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close